Nomura Asset Management Co. Ltd. Has $2.96 Million Stake in Solventum Co. (NYSE:SOLV)

Nomura Asset Management Co. Ltd. increased its position in Solventum Co. (NYSE:SOLV) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,741 shares of the company’s stock after buying an additional 300 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Solventum were worth $2,956,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SOLV. New Age Alpha Advisors LLC bought a new position in Solventum during the fourth quarter valued at about $92,000. Kiltearn Partners LLP raised its stake in shares of Solventum by 80.6% in the 4th quarter. Kiltearn Partners LLP now owns 73,500 shares of the company’s stock valued at $4,855,000 after acquiring an additional 32,800 shares in the last quarter. Norges Bank acquired a new stake in Solventum in the 4th quarter worth approximately $203,740,000. Caisse Des Depots ET Consignations bought a new stake in Solventum during the fourth quarter worth approximately $83,000. Finally, NEOS Investment Management LLC grew its holdings in Solventum by 24.1% during the fourth quarter. NEOS Investment Management LLC now owns 6,359 shares of the company’s stock valued at $420,000 after purchasing an additional 1,236 shares during the last quarter.

Wall Street Analyst Weigh In

SOLV has been the subject of several recent analyst reports. Wells Fargo & Company upped their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Bank of America lifted their price objective on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group increased their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Finally, Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Solventum has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Price Performance

Shares of NYSE:SOLV opened at $76.54 on Thursday. The firm has a market capitalization of $13.24 billion and a PE ratio of 27.83. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The business’s 50 day moving average is $75.66 and its 200-day moving average is $72.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.